Cost of Severe Hypoglycaemia in Type 1 Diabetes in Spain
Author Information
Author(s): J. Reviriego, R. Gomis, J. P. Marañés, W. Ricart, P. Hudson, J. A. Sacristán
Primary Institution: Lilly S.A.
Hypothesis
To determine the costs of severe hypoglycaemia in patients with type 1 diabetes and the cost-effectiveness of insulin lispro compared to regular insulin.
Conclusion
The use of insulin lispro is associated with reductions in annual costs due to fewer severe hypoglycaemia episodes.
Supporting Evidence
- The overall mean cost per episode of severe hypoglycaemia was €366.
- Insulin lispro showed a lower incidence of severe hypoglycaemia compared to regular insulin.
- Direct costs accounted for 65.4% of the total costs associated with severe hypoglycaemia.
Takeaway
This study shows that using a special type of insulin can help save money by preventing serious low blood sugar problems.
Methodology
A retrospective study reviewing clinical records of 100 type 1 diabetic patients from three Spanish health centres.
Limitations
The study only reviewed data from three centres, which may not represent the entire Spanish population.
Participant Demographics
51% male and 49% female, mean age 33.22 years, mean diabetes duration 16.9 years.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI of €124–380 for direct costs and €211–551 for total costs.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website